GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TG Therapeutics Inc (NAS:TGTX) » Definitions » Shiller PE Ratio

TG Therapeutics (TG Therapeutics) Shiller PE Ratio : (As of May. 16, 2024)


View and export this data going back to 1995. Start your Free Trial

What is TG Therapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


TG Therapeutics Shiller PE Ratio Historical Data

The historical data trend for TG Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TG Therapeutics Shiller PE Ratio Chart

TG Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

TG Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of TG Therapeutics's Shiller PE Ratio

For the Biotechnology subindustry, TG Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TG Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TG Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where TG Therapeutics's Shiller PE Ratio falls into.



TG Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

TG Therapeutics's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, TG Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.07/131.7762*131.7762
=-0.070

Current CPI (Mar. 2024) = 131.7762.

TG Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -0.360 100.560 -0.472
201409 -0.510 100.428 -0.669
201412 -0.480 99.070 -0.638
201503 -0.350 99.621 -0.463
201506 -0.380 100.684 -0.497
201509 -0.280 100.392 -0.368
201512 -0.370 99.792 -0.489
201603 -0.280 100.470 -0.367
201606 -0.330 101.688 -0.428
201609 -0.500 101.861 -0.647
201612 -0.480 101.863 -0.621
201703 -0.520 102.862 -0.666
201706 -0.450 103.349 -0.574
201709 -0.480 104.136 -0.607
201712 -0.460 104.011 -0.583
201803 -0.590 105.290 -0.738
201806 -0.590 106.317 -0.731
201809 -0.430 106.507 -0.532
201812 -0.690 105.998 -0.858
201903 -0.430 107.251 -0.528
201906 -0.420 108.070 -0.512
201909 -0.690 108.329 -0.839
201912 -0.440 108.420 -0.535
202003 -0.485 108.902 -0.587
202006 -0.470 108.767 -0.569
202009 -0.730 109.815 -0.876
202012 -0.710 109.897 -0.851
202103 -0.690 111.754 -0.814
202106 -0.590 114.631 -0.678
202109 -0.650 115.734 -0.740
202112 -0.700 117.630 -0.784
202203 -0.510 121.301 -0.554
202206 -0.300 125.017 -0.316
202209 -0.260 125.227 -0.274
202212 -0.390 125.222 -0.410
202303 -0.280 127.348 -0.290
202306 -0.340 128.729 -0.348
202309 0.730 129.860 0.741
202312 -0.100 129.419 -0.102
202403 -0.070 131.776 -0.070

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


TG Therapeutics  (NAS:TGTX) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


TG Therapeutics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of TG Therapeutics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


TG Therapeutics (TG Therapeutics) Business Description

Traded in Other Exchanges
Address
3020 Carrington Mill boulevard, Suite 475, Morrisville, NC, USA, 27560
TG Therapeutics Inc is a fully-integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial.
Executives
Laurence N Charney director MARVEL ENTERTAINMENT, INC., 417 FIFTH AVENUE, NEW YORK NY 10016
Sean A Power officer: CFO, Secretary and Treasurer 787 SEVENTH AVENUE, 48TH FLOOR, NEW YORK NY 10019
Michael S Weiss director, officer: CEO and President 750 LEXINGTON AVE, NEW YORK NY 10022
Sagar Lonial director C/O TG THERAPEUTICS, INC., 2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK NY 10014
Yann Echelard director C/O LFB BIOTECHNOLOGIES, S.A.S., 3, AVENUE DES TROPIQUES LES ULIS, COURTABOEUF I0 91958
Ra Capital Management, L.p. 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Kenneth Hoberman director 750 LEXINGTON AVENUE, 6TH FLOOR, NEW YORK NY 10024
Daniel Hume director 3 COLUMBUS CIRCLE, 15TH FLOOR, NEW YORK NY 10019
William James Kennedy director C/O XTL BIOPHARMACEUTICALS LTD, 711 EXECUTIVE BLVD., SUITE Q, VALLEY COTTAGE NY 10989
Ra Capital Healthcare Fund Lp 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Rajeev M. Shah 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Peter Kolchinsky 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Lfb Biotechnologies S.a.s.u. 10 percent owner 3 AVENUE DES TROPIQUES, LES ULIS, COURTABOEUF I0 91958
Mark Schoenebaum director 787 SEVENTH AVENUE, 48TH FLOOR, NEW YORK NY 10019
Opus Point Partners, Llc 10 percent owner 787 7TH AVENUE, 48TH FLOOR, NEW YORK NY 10019

TG Therapeutics (TG Therapeutics) Headlines

From GuruFocus